Antibody validation for successful immunohistochemistry and multiplex immunofluorescence
Event Date: May 16, 2021
Dr. Mike Spencer, Director of Immunohistochemistry and Digital Pathology at Fortis Life Sciences, discusses key considerations for mIF antibody validation and optimization.
Advances in cancer treatment using immunotherapies has accelerated the need to examine the tumor immune microenvironment (TME). Multiplex immunofluorescence (mIF) assays allow the researcher to examine the spatial biology of tissues to determine tumor and immune cell interactions. Successful application of this technique requires highly validated immunohistochemistry antibodies to ensure optimal assay results.
Dr. Mike Spencer, Director of Immunohistochemistry and Digital Pathology at Fortis Life Sciences discusses key considerations for mIF antibody validation and optimization.
Learning objectives:
- Gain insight into the quality issues surrounding antibodies and their validation
- Understand how to evaluate and select the correct monoclonal antibody for use in mIF assays
- Learn a faster, effective approach to optimize antibodies for use in immune checkpoint multiplex assays, resulting in half the time typically spent on validating multiplex panels
Speaker: Dr. Mike Spencer, Director of Immunohistochemistry and Digital Pathology
Dr. Mike Spencer received his doctorate in Molecular and Cellular Biochemistry from the University of Kentucky. The immunohistochemistry lab at Fortis Life Sciences validates the performance of new Bethyl antibody products in immunohistochemistry and immunocytochemistry applications.
Dr. Spencer has been integral in extending the capabilities of immunochemistry lab to include multiplex immunoassays for spatial biology.
Watch this on-demand webinar:
